Study | country | Study design | Age (mean) | N |
---|---|---|---|---|
Abraham_2011 [14] | USA | Retrospective | 74.5 | 60,265 |
Aburub_2020 [15] | Canada | Cross-sectional | 69.3 | 175 |
Anderson_2022 [16] | USA | Cross-sectional | 75(median) | 1024 |
Arora_2022 [17] | USA | Cross-sectional | 70 | 505 |
Arrieta_2019 [18] | France | Randomized clinical trial | 76.7 | 301 |
Bartlett_2020 [19] | USA | Retrospective | 75.8 | 425 |
Basal_2019 [20] | USA | Prospective | 63 | 667 |
Bjerre_2019 [21] | Denmark | Randomized clinical trial | 68.4 | 214 |
Blackwood_2021 [22] | USA | Prospective | 72.62 | 34 |
Bluethmann_2020 [23] | USA | Cross-sectional | 74.4 | 1203 |
Bylow_2008 [24] | USA | Prospective | 78(median) | 50 |
Chen_2014 [25] | USA | Prospective | 75.41 | 1630 |
Childs_2021 [26] | USA | Retrospective | 62 | 300 |
Cobbing_2024 [27] | Canada | Prospective | 74 | 198 |
Eriksen_2022 [28] | Norway | Prospective | 73.6 | 298 |
Fagard_2017 [29] | Belgium | Prospective | 77(median) | 115 |
Fahimnia_2018 [30] | USA | Retrospective | 80(median) | 806 |
Farcet_2016 [31] | France | Cross-sectional | 83.2 | 217 |
Feliu_2021 [32] | Spain | Prospective | 77(median) | 493 |
Gewandter_2015 [33] | USA | Retrospective | 80(median) | 103 |
Godby_2021 [34] | USA | Cross-sectional | 70.0 | 355 |
Grothe_2014 [35] | Germany | Retrospective | 70 | 285 |
Guerard_2015 [36] | USA | Cross-sectional | 71(median) | 528 |
Gupta_2023 [37] | USA | Retrospective | 62(median) | 1571 |
Habib_2024 [38] | Canada | Cross-sectional | 75.4 | 320 |
Hamid_2022 [39] | Ireland | Retrospective | 76.49 | 94 |
Hines_2024 [40] | USA | Retrospective | 71.7 | 4792 |
Huang_2017 [41] | USA | Cross-sectional | 74.2 | 12,659 |
Hurria_2009 [42] | USA | Prospective | 73 | 500 |
Hussain_2010 [9] | Canada | Prospective | 69.6 | 260 |
Isleyen_2023 [43] | Turkey | Cross-sectional | 73.0 | 180 |
Jensen-Battaglia_2022 [44] | USA | Randomized clinical trial | 75.88 | 541 |
Jespersen_2021 [45] | Denmark | Prospective | 75.5(median) | 170 |
Ji_2024 [4] | USA | Prospective | 70 | 497 |
Jolly_2015 [46] | Canada | Cross-sectional | 77 | 90 |
Jun_2018 [47] | Korea | Retrospective | 62.1 | 356 |
Kalariya_2024 [48] | USA | Retrospective | 78.1 | 156 |
Kenis_2022 [49] | Belgium | Prospective | 80.0(median) | 3681 |
Kikuchi_2019 [50] | USA | Retrospective | 76 | 429 |
Kim_2022 [51] | USA | Randomized clinical trial | 68 | 122 |
Komatsu_2018 [52] | Japan | Cross-sectional | 68 | 98 |
Kong_2014 [53] | China | Prospective | Not available | 52 |
Korc-Grodzicki_2015 [54] | USA | Retrospective | 80(median) | 416 |
Liu_2023 [55] | China | Cross-sectional | 71.29 | 161 |
LoConte_2013 [56] | USA | Retrospective |  > 64 | 36,781 |
Loh_2017 [57] | USA | Cross-sectional | 81(median) | 389 |
Lund_2024 [58] | Denmark | Prospective | 74 | 238 |
Mariano_2015 [59] | Canada | Prospective | 77 | 90 |
MartÃ-Dillet_2023 [60] | Spain | Prospective | Not available | 117 |
May_2020 [61] | Ireland | Prospective | 77.7 | 174 |
Mir_2020 [62] | USA | Cross-sectional | 70 | 264 |
Mohamed_2024 [63] | USA | Randomized clinical trial | 77.2 | 616 |
Mohile_2011 [8] | USA | Cross-sectional | 76.19 | 2349 |
Nassani_2013 [64] | Lebanon | Cross-sectional | 76(median) | 100 |
Overcash_2007 [65] | USA | Prospective | 77.6 | 165 |
Paillaud_2014 [66] | France | Prospective | 80.0 | 519 |
Pan_2020 [67] | USA | Randomized clinical trial | 70 | 2019 |
Pandya_2016 [68] | USA | Cross-sectional | 78.5 | 24,271 |
Patel_2015 [69] | Australia | Retrospective | 77(median) | 385 |
Pautex_2008 [70] | Switzerland | Prospective | 71.0 | 198 |
Peeters_2019 [71] | Belgium | Prospective |  > 70 | 3681 |
Pergolotti_2014 [72] | USA | Retrospective | 71(median) | 524 |
Piper_2024 [73] | Denmark | Cross-sectional | 74.4 | 200 |
Pollock_2023 [74] | USA | Randomized clinical trial | 74.0(median) | 803 |
Rattanakrong_2022 [75] | Thailand | Prospective | Not available | 123 |
Reyes_2023 [76] | USA | Retrospective | 67.7 | 83 |
Rosko_2019 [77] | USA | Prospective | Not available | 100 |
Saarelainen_2014 [78] | Australia | Prospective | 76.7 | 383 |
Sattar_2019 [79] | Canada | Cross-sectional | 76(median) | 100 |
Spoelstra_2010 [7] | USA | Cross-sectional | 79.5 | 911 |
Sulicka_2018 [80] | Poland | Cross-sectional | 79.4 | 286 |
Tennison_2021 [81] | USA | Prospective | Not available | 198 |
Tomczak_2021 [82] | USA | Prospective | 72.2 | 51 |
Turner_2016 [83] | Australia | Cross-sectional | 76.7 | 385 |
Vande Walle_2014 [84] | Belgium | Prospective | 76 | 937 |
Vetrano_2016 [85] | Europe | Retrospective | 82.2 | 802 |
Villani_2022 [86] | Italy | Cross-sectional | 83.4 | 442 |
Whittle_2017 [87] | UK | Prospective | 73.9 | 417 |
Wildes_2018 [3] | USA | Case–control | 76.4 | 234 |
Wildes_2018 [88] | USA | Cross-sectional | 73 | 498 |
Williams_2015 [89] | USA | Prospective | 73 | 1172 |
Williams_2020 [90] | USA | Prospective | 70.1(median) | 336 |
Winters-Stone_2011 [91] | USA | Retrospective | Not available | 143 |
Wu_2016 [92] | Taiwan | Retrospective | 74.2 | 1748 |
Zak_2017 [93] | Poland | Cross-sectional | 70.2 | 102 |
Zhang_2018 [94] | USA | Retrospective | 78.4 | 304 |